YOLFTbeta
Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc.

DNTH · NASDAQ · Healthcare / Biotechnology

91.81USD-0.67 (-0.72%)

Price History

Full chart

Market Stats

Previous Close92.48
Open91.87
Day Range88.61 – 92.34
52-Week Range32.22 – 117.88
Volume680.56K
Market Cap4.95B
P/E (TTM)0.00
Forward P/E0.00
EPS-4.24
Dividend Yield0.00%
Beta0.06
50-Day Avg106.44
200-Day Avg79.79

About

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Marino Garcia M.B.A.
  • Employees92
  • Headquarters7 Times Square, New York, NY, United States, 10036, USA
  • Websitehttps://dianthustx.com

Leadership

  • Mr. Marino Garcia M.B.A.President, CEO & Director · b. 1966
  • Mr. Ryan SavitzExecutive VP, CFO, Chief Business Officer & Treasurer · b. 1989
  • Dr. Simrat Randhawa M.B.A., M.D.Executive VP and Head of R&D · b. 1970
  • Mr. Edward G. CarrSenior VP & Chief Accounting Officer · b. 1969
  • Mr. Judson TaylorSenior VP & Head of Technical Operations
  • Ms. Jennifer Davis RuffVP and Head of Investor Relations & Corporate Affairs
  • Mr. Adam M. Veness Esq.Senior VP, General Counsel & Secretary · b. 1986
  • Ms. Kristina MaximenkoChief People Officer
  • Ms. Rashieda GluckHead of Clinical Development Operations
  • Mr. Scott Nogi M.B.A.Head of Business Operations

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----1.48M6.42M2.83M6.24M2.04M
Growth (%)------+334.76%-55.96%+120.63%-67.35%
Cost of Revenue6.00K376.00K875.00K1.84M1.98M2.02M147.00K355.00K412.00K-
Gross Profit-6.00K-376.00K-875.00K-1.84M-1.98M1.48M6.42M2.83M6.24M2.04M
Gross Margin-----100.00%100.00%100.00%100.00%100.00%
Operating Expense9.26M35.35M59.09M81.13M76.72M14.56M36.12M51.00M108.10M179.97M
Operating Income-9.27M-35.73M-59.96M-82.97M-78.70M-13.09M-29.70M-48.17M-101.86M-177.93M
Operating Margin------886.59%-462.91%-1704.67%-1633.74%-8739.34%
EBITDA-9.26M-35.12M-56.64M-74.93M-72.96M-11.09M-28.33M-43.20M-84.56M-161.91M
EBITDA Margin------751.29%-441.47%-1528.66%-1356.17%-7952.31%
Net Income-9.43M-35.49M-57.52M-76.77M-74.94M-13.11M-28.48M-43.55M-84.97M-162.34M
Net Income Margin------888.14%-443.76%-1541.22%-1362.77%-7973.33%
R&D5.78M27.90M41.34M57.37M48.64M12.61M29.38M32.84M83.11M145.64M
R&D as % of Total Revenue-----854.07%457.83%1162.10%1332.88%7153.14%
Interest Expense163.00K---3.77M3.56M----
Interest Expense % of Total Revenue-----240.92%----

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.34M54.46M157.31M161.51M161.62M189.93M83.11M179.41M374.01M530.92M
Total Liabilities2.30M4.14M11.66M20.32M17.71M17.26M9.45M10.54M21.53M37.52M
Total Equity9.04M50.32M145.65M141.19M143.91M172.67M73.66M168.87M352.48M493.40M
Cash4.54M51.57M58.34M65.07M58.15M131.65M15.37M132.32M22.79M51.09M
Total Debt------788.00K585.00K1.49M1.39M
Net Debt-4.54M-51.57M-58.34M-65.07M-58.15M-131.65M-14.58M-131.74M-21.30M-49.70M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.53M-22.26M-41.89M-57.10M-64.02M-59.53M-29.07M-36.86M-78.18M-129.06M
Investing Cash Flow-139.00K-2.20M-91.70M1.53M-10.63M43.43M-59.82M20.25M-286.81M-122.83M
Financing Cash Flow10.71M71.49M142.15M62.30M67.74M89.60M96.68M133.57M255.62M280.13M
Capital Expenditure139.00K2.20M7.67M3.06M400.00K1.26M139.00K110.00K105.00K213.00K
Free Cash Flow-6.67M-24.46M-49.56M-60.16M-64.42M-60.80M-29.21M-36.97M-78.28M-129.27M
FCF to OCF102.13%109.88%118.32%105.36%100.62%102.12%100.48%100.30%100.13%100.17%

Earnings

Report DateMay 4, 2017Feb 3, 2018May 30, 2018Aug 9, 2018Nov 8, 2018Mar 19, 2019May 9, 2019Aug 8, 2019Nov 13, 2019Mar 3, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Mar 3, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 8, 2022May 16, 2022Aug 4, 2022Nov 3, 2022Mar 7, 2023May 11, 2023Sep 18, 2023Nov 9, 2023Mar 21, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 19, 2025May 12, 2025Aug 7, 2025Nov 5, 2025Mar 9, 2026May 5, 2026Aug 4, 2026Nov 4, 2026
EPS Estimate0.000.000.00-1.13-0.67-0.53-0.55-0.49-0.53-0.58-0.60-0.54-0.43-0.39-0.39-0.37-0.33-0.32-0.32-0.34-0.29-0.28-0.40-3.04-0.56-1.01-0.44-0.55-0.60-0.76-0.71-0.86-0.86-1.03-1.10-0.93-1.01
EPS Actual-0.15-1.03-4.45-3.13-0.49-0.50-0.44-0.48-0.54-0.59-0.51-0.48-0.37-0.38-0.36-0.32-0.30-0.33-0.39-0.29-0.27-0.30-0.47-0.87-3.78-0.71-0.54-0.51-0.74-0.81-0.82-0.88-0.97-1.43-0.85-0.90-
Surprise----176.99%26.87%5.66%20.00%2.04%-1.89%-1.72%15.00%11.11%13.95%2.06%7.22%14.09%8.68%-4.13%-22.60%14.71%6.90%-8.62%-17.50%71.50%-575.00%29.70%-22.73%7.27%-23.33%-6.58%-15.49%-2.33%-12.79%-38.65%22.73%3.23%-
Timing------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap4.95B
Enterprise Value4.34B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2542.38
Price / Book4.46
EPS-4.24
Book Value21.39
Revenue (TTM)1.90M
Gross Profit (TTM)1.90M
EBITDA-217.72M
Profit Margin0.00%
Operating Margin-8079.11%
Return on Equity-26.07%
Return on Assets-17.69%
Shares Outstanding55.93M
Shares Float55.85M
Beta0.06
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 12 analystsTarget 140.80
  • Strong Buy
    10
  • Buy
    2

Ownership Breakdown

Institutions
128.17%
Insiders
0.12%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    7.77M13.89%
  • Wellington Management Company LLP
    3.23M5.77%
  • BlackRock Inc
    3.18M5.68%
  • RA Capital Management, LLC
    2.61M4.67%
  • Fairmount Funds Management LLC
    2.54M4.54%
  • Avidity Partners Management LP
    2.10M3.76%
  • Vanguard Capital Management, LLC
    2.03M3.63%
  • Octagon Capital Advisors LP
    1.84M3.29%
  • TCG Crossover Management, LLC
    1.68M3.00%
  • State Street Corp
    1.40M2.50%
  • T. Rowe Price Investment Management,Inc.
    1.29M2.31%
  • VR Adviser, LLC
    1.18M2.11%
  • Fred Alger Management, LLC
    1.16M2.08%

Top Fund Holders

  • T. Rowe Price Capital Appreciation
    1.76M3.14%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.65M2.96%
  • Fidelity Growth Company Fund
    1.59M2.85%
  • Vanguard Health Care Inv
    1.50M2.69%
  • State Street® SPDR® S&P® Biotech ETF
    1.37M2.45%
  • T. Rowe Price Small-Cap Stock
    1.23M2.21%
  • iShares Russell 2000 ETF
    1.21M2.15%

Stock Splits

  • Sep 12, 20231:16